FT Options Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
Similar funds
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.